Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
Identifieur interne : 000157 ( Main/Exploration ); précédent : 000156; suivant : 000158Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
Auteurs : Jingsheng Hua [République populaire de Chine] ; Weiqing Qian [République populaire de Chine] ; Xiaoxia Wu [République populaire de Chine] ; Lili Zhou [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Suning Chen [République populaire de Chine] ; Jian Zhang [République populaire de Chine] ; Huiying Qiu [République populaire de Chine]Source :
- OncoTargets and therapy [ 1178-6930 ] ; 2020.
Abstract
Pediatric Philadelphia chromosome-like (Ph-like) acute B-lymphoblastic leukemia (B-ALL), a high-risk subset of B-ALL characterized by a gene expression profile similar to that of Ph-positive ALL, has extremely poor outcome after a relapse following autologous chimeric antigen receptor (CAR)-T and haploidentical (haplo) hematopoietic stem cell transplantation(HSCT)therapy. with very limited treatment options. Donor-derived CAR T-cell therapy, the most vital advanced anticancer technology, may be a promising salvage strategy for patients with Ph-like B-ALL. Here, we presented a relapsed and refractory case of a child with Ph-like B-ALL after autologous anti-CD19 CAR T-cell therapy followed by haplo-HSCT. She successfully achieved the fourth complete remission (CR4) and maintained CR for five months after the sequential infusion of donor-derived anti-CD22 and anti-CD19 CAR T cells, with mild CRS side effects and no obvious graft-versus-host disease. A donor-derived anti-CD22 and -CD19 CAR T-cell therapy combined with a sequential infusion strategy may provide a promising alternative treatment strategy as effective and safe salvage therapy for children with recurrent and refractory Ph-like B-ALL after autologous CD19-directed CAR T-cell therapy followed by haplo-HSCT.
Url:
DOI: 10.2147/OTT.S235882
PubMed: 32256082
PubMed Central: 7098167
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000626
- to stream Pmc, to step Curation: 000626
- to stream Pmc, to step Checkpoint: 000093
- to stream Ncbi, to step Merge: 002B06
- to stream Ncbi, to step Curation: 002B06
- to stream Ncbi, to step Checkpoint: 002B06
- to stream Main, to step Merge: 000157
- to stream Main, to step Curation: 000157
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature</title><author><name sortKey="Hua, Jingsheng" sort="Hua, Jingsheng" uniqKey="Hua J" first="Jingsheng" last="Hua">Jingsheng Hua</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Hematology, Taizhou Municipal Hospital</institution>,<addr-line>Taizhou</addr-line><addr-line>318000</addr-line>,<addr-line>Zhejiang</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Qian, Weiqing" sort="Qian, Weiqing" uniqKey="Qian W" first="Weiqing" last="Qian">Weiqing Qian</name><affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Suzhou Vocational Health College</institution>,<addr-line>Suzhou</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Wu, Xiaoxia" sort="Wu, Xiaoxia" uniqKey="Wu X" first="Xiaoxia" last="Wu">Xiaoxia Wu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zhou, Lili" sort="Zhou, Lili" uniqKey="Zhou L" first="Lili" last="Zhou">Lili Zhou</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Yu, Lei" sort="Yu, Lei" uniqKey="Yu L" first="Lei" last="Yu">Lei Yu</name><affiliation wicri:level="1"><nlm:aff id="AFF0004"><institution>College of Chemistry and Molecular Engineering, East China Normal University</institution>,<addr-line>Shanghai</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Suning" sort="Chen, Suning" uniqKey="Chen S" first="Suning" last="Chen">Suning Chen</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Jian" sort="Zhang, Jian" uniqKey="Zhang J" first="Jian" last="Zhang">Jian Zhang</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Qiu, Huiying" sort="Qiu, Huiying" uniqKey="Qiu H" first="Huiying" last="Qiu">Huiying Qiu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32256082</idno><idno type="pmc">7098167</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098167</idno><idno type="RBID">PMC:7098167</idno><idno type="doi">10.2147/OTT.S235882</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000626</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000626</idno><idno type="wicri:Area/Pmc/Curation">000626</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000626</idno><idno type="wicri:Area/Pmc/Checkpoint">000093</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000093</idno><idno type="wicri:Area/Ncbi/Merge">002B06</idno><idno type="wicri:Area/Ncbi/Curation">002B06</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B06</idno><idno type="wicri:Area/Main/Merge">000157</idno><idno type="wicri:Area/Main/Curation">000157</idno><idno type="wicri:Area/Main/Exploration">000157</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature</title><author><name sortKey="Hua, Jingsheng" sort="Hua, Jingsheng" uniqKey="Hua J" first="Jingsheng" last="Hua">Jingsheng Hua</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Hematology, Taizhou Municipal Hospital</institution>,<addr-line>Taizhou</addr-line><addr-line>318000</addr-line>,<addr-line>Zhejiang</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Qian, Weiqing" sort="Qian, Weiqing" uniqKey="Qian W" first="Weiqing" last="Qian">Weiqing Qian</name><affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Suzhou Vocational Health College</institution>,<addr-line>Suzhou</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Wu, Xiaoxia" sort="Wu, Xiaoxia" uniqKey="Wu X" first="Xiaoxia" last="Wu">Xiaoxia Wu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zhou, Lili" sort="Zhou, Lili" uniqKey="Zhou L" first="Lili" last="Zhou">Lili Zhou</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Yu, Lei" sort="Yu, Lei" uniqKey="Yu L" first="Lei" last="Yu">Lei Yu</name><affiliation wicri:level="1"><nlm:aff id="AFF0004"><institution>College of Chemistry and Molecular Engineering, East China Normal University</institution>,<addr-line>Shanghai</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Suning" sort="Chen, Suning" uniqKey="Chen S" first="Suning" last="Chen">Suning Chen</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Jian" sort="Zhang, Jian" uniqKey="Zhang J" first="Jian" last="Zhang">Jian Zhang</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Qiu, Huiying" sort="Qiu, Huiying" uniqKey="Qiu H" first="Huiying" last="Qiu">Huiying Qiu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University</institution>,<addr-line>Suzhou</addr-line><addr-line>215006</addr-line>,<addr-line>Jiangsu</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">OncoTargets and therapy</title><idno type="eISSN">1178-6930</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>Pediatric Philadelphia chromosome-like (Ph-like) acute B-lymphoblastic leukemia (B-ALL), a high-risk subset of B-ALL characterized by a gene expression profile similar to that of Ph-positive ALL, has extremely poor outcome after a relapse following autologous chimeric antigen receptor (CAR)-T and haploidentical (haplo) hematopoietic stem cell transplantation(HSCT)therapy. with very limited treatment options. Donor-derived CAR T-cell therapy, the most vital advanced anticancer technology, may be a promising salvage strategy for patients with Ph-like B-ALL. Here, we presented a relapsed and refractory case of a child with Ph-like B-ALL after autologous anti-CD19 CAR T-cell therapy followed by haplo-HSCT. She successfully achieved the fourth complete remission (CR4) and maintained CR for five months after the sequential infusion of donor-derived anti-CD22 and anti-CD19 CAR T cells, with mild CRS side effects and no obvious graft-versus-host disease. A donor-derived anti-CD22 and -CD19 CAR T-cell therapy combined with a sequential infusion strategy may provide a promising alternative treatment strategy as effective and safe salvage therapy for children with recurrent and refractory Ph-like B-ALL after autologous CD19-directed CAR T-cell therapy followed by haplo-HSCT.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Hua, Jingsheng" sort="Hua, Jingsheng" uniqKey="Hua J" first="Jingsheng" last="Hua">Jingsheng Hua</name></noRegion><name sortKey="Chen, Suning" sort="Chen, Suning" uniqKey="Chen S" first="Suning" last="Chen">Suning Chen</name><name sortKey="Hua, Jingsheng" sort="Hua, Jingsheng" uniqKey="Hua J" first="Jingsheng" last="Hua">Jingsheng Hua</name><name sortKey="Qian, Weiqing" sort="Qian, Weiqing" uniqKey="Qian W" first="Weiqing" last="Qian">Weiqing Qian</name><name sortKey="Qiu, Huiying" sort="Qiu, Huiying" uniqKey="Qiu H" first="Huiying" last="Qiu">Huiying Qiu</name><name sortKey="Wu, Xiaoxia" sort="Wu, Xiaoxia" uniqKey="Wu X" first="Xiaoxia" last="Wu">Xiaoxia Wu</name><name sortKey="Yu, Lei" sort="Yu, Lei" uniqKey="Yu L" first="Lei" last="Yu">Lei Yu</name><name sortKey="Zhang, Jian" sort="Zhang, Jian" uniqKey="Zhang J" first="Jian" last="Zhang">Jian Zhang</name><name sortKey="Zhou, Lili" sort="Zhou, Lili" uniqKey="Zhou L" first="Lili" last="Zhou">Lili Zhou</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000157 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000157 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:7098167
|texte= Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32256082" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |